Cardiovascular Drugs

Cardiovascular drugs represent one of the largest and most clinically important pharmacological classes, encompassing agents that modify cardiac contractility, vascular tone, conduction, and hemodynamics to treat the spectrum of cardiovascular disease. These medications are among the most commonly prescribed in clinical practice, with prevalence of use exceeding 50% in patients over age 65 years, reflecting the high burden of hypertension, coronary artery disease, arrhythmias, and heart failure globally. The cardiovascular drug classes include beta-blockers, ACE inhibitors, angiotensin receptor blockers, calcium channel blockers, diuretics, statins, antiplatelet agents, anticoagulants, inotropes, vasopressors, and antiarrhythmic agents, each with distinct mechanisms targeting different pathophysiological derangements. Mastery of cardiovascular pharmacology is essential for clinical practice because these agents are foundational to managing acute coronary syndromes, hypertensive emergencies, decompensated heart failure, arrhythmias, and chronic disease prevention, and inappropriate use carries substantial morbidity and mortality risk. Understanding drug mechanisms, indications, contraindications, drug-drug interactions, and adverse effects is critical for board examinations and optimal patient outcomes. This comprehensive reference covers the major cardiovascular drug classes, their pharmacological mechanisms, clinical applications, and evidence-based therapeutic strategies.

Understanding cardiovascular drug mechanisms requires knowledge of the fundamental physiology governing cardiac function and vascular biology:

The sympathetic nervous system modulates cardiac contractility, heart rate, and vascular tone through activation of α1, α2, β1, and β2 adrenergic receptors. β1-receptors on cardiac myocytes increase contractility and heart rate through G-protein coupled signaling leading to increased intracellular cAMP, enhanced calcium influx, and accelerated relaxation. α1-receptors on vascular smooth muscle cause vasoconstriction via phospholipase C activation and increased intracellular calcium. The parasympathetic nervous system (vagus nerve) via muscarinic receptors decreases heart rate and AV nodal conduction through increased potassium conductance and decreased cAMP. Beta-blockers competitively inhibit β1-adrenergic receptors, reducing cardiac oxygen demand, decreasing automatic firing in ectopic foci, and slowing AV nodal conduction, thereby reducing heart rate and blood pressure. Alpha-blockers prevent α1-mediated vasoconstriction, causing direct vasodilation and blood pressure reduction. This sympathetic/parasympathetic balance is fundamental to understanding how cardiovascular drugs modulate cardiac hemodynamics.

The RAAS is a critical regulator of blood pressure, fluid volume, and cardiac remodeling. When renal perfusion pressure decreases, juxtaglomerular cells release renin, which cleaves angiotensinogen to form angiotensin I (Ang I). The angiotensin-converting enzyme (ACE) in the pulmonary endothelium converts Ang I to the potent vasoconstrictor angiotensin II (Ang II). Ang II acts on AT1 receptors to cause systemic and renal vasoconstriction, increase aldosterone secretion (promoting sodium retention and hypokalemia), enhance sympathetic outflow, and promote cardiac and vascular fibrosis. ACE inhibitors block ACE, preventing Ang II formation and reducing circulating and local (tissue) levels of this hormone. Angiotensin receptor blockers (ARBs) selectively block AT1 receptors, preventing Ang II's effects while allowing unopposed AT2 receptor signaling (which promotes vasodilation and cardiac protection). Aldosterone antagonists (spironolactone, eplerenone) block mineralocorticoid receptors in the collecting duct, preventing sodium retention and potassium loss. Direct renin inhibitors (aliskiren) inhibit renin activity upstream, reducing formation of Ang I. These agents are cardioprotective in heart failure and hypertension because they prevent maladaptive remodeling and reduce afterload.

Nitric oxide (NO) is a critical endothelial-derived vasodilator produced by nitric oxide synthase (NOS) from L-arginine. NO diffuses into vascular smooth muscle and activates guanylate cyclase, increasing cyclic GMP (cGMP) and leading to smooth muscle relaxation and vasodilation. Phosphodiesterase-5 (PDE-5) inhibitors and soluble guanylate cyclase activators enhance this pathway. Organic nitrates (nitroglycerin, isosorbide dinitrate) are prodrugs that release NO in vascular tissue, directly causing vasodilation of both epicardial coronary arteries and resistance vessels, reducing preload and afterload. Chronic nitrate use leads to nitrate tolerance, likely due to diminished bioconversion of nitrates to active NO, underscoring the importance of a nitrate-free interval. The endothelium in patients with atherosclerosis, hypertension, and diabetes has impaired NO synthesis, contributing to vasoconstriction and thrombosis.

Cardiac contractility depends on L-type calcium channels in the sarcolemma, which allow calcium influx during the action potential plateau phase. This triggers calcium-induced calcium release (CICR) from the sarcoplasmic reticulum, increasing cytoplasmic calcium concentration and promoting myofilament cross-bridging and contraction. Calcium channel blockers (CCBs) inhibit L-type calcium channels in cardiac and vascular smooth muscle. Dihydropyridines (amlodipine, nifedipine) cause preferential vasodilation with minimal cardiac effects due to their peripheral selectivity. Non-dihydropyridines (verapamil, diltiazem) depress cardiac contractility and conduction, particularly at the AV node. In vascular smooth muscle, CCB-induced reduction in intracellular calcium prevents cross-bridge cycling and causes vasodilation with blood pressure reduction and improved coronary perfusion. Understanding calcium handling is essential for recognizing CCB contraindications in patients with severe systolic dysfunction or heart block.

Cardiac action potentials depend on precise regulation of sodium, potassium, and calcium channels. Phase 0 depolarization is mediated by fast sodium channels; Class I antiarrhythmics (sodium channel blockers) slow phase 0 slope, slowing conduction velocity throughout the heart and reducing automaticity. Phase 3 repolarization is mediated by potassium channels; Class III antiarrhythmics block potassium channels, prolonging the action potential duration and refractory period, thereby suppressing reentrant arrhythmias. The AV node has slow calcium-dependent conduction; beta-blockers and non-dihydropyridine CCBs slow AV nodal conduction by reducing calcium influx, making them effective for supraventricular arrhythmias. Digoxin increases parasympathetic tone and slows AV nodal conduction through vagomimetic effects, while its positive inotropic effects (via Na-K-ATPase inhibition) are now considered less important in modern heart failure therapy.

Loop diuretics (furosemide, torsemide) inhibit the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, blocking sodium reabsorption and preventing the osmotic gradient that drives water reabsorption. They are the most potent diuretics and preferentially eliminate potassium and magnesium, predisposing to hypokalemia and arrhythmias. Thiazide diuretics (hydrochlorothiazide) inhibit the Na-Cl cotransporter in the distal convoluted tubule and cause modest sodium and water loss, with lesser potassium wasting than loop diuretics. Potassium-sparing diuretics (amiloride, triamterene, spironolactone) block sodium channels or aldosterone, preventing potassium loss. In heart failure, diuretics reduce pulmonary and systemic congestion by decreasing intravascular volume and ventricular filling pressures, alleviating dyspnea and edema, though excessive diuresis may impair renal perfusion and activate neurohormonal systems.

Statins (HMG-CoA reductase inhibitors) competitively inhibit the rate-limiting step of cholesterol synthesis, reducing intracellular cholesterol levels and triggering upregulation of LDL receptors, thereby increasing clearance of circulating LDL cholesterol. Beyond cholesterol lowering, statins have pleiotropic anti-inflammatory effects, including reduced expression of adhesion molecules and cytokines, stabilization of atherosclerotic plaques, and improved endothelial function. These mechanisms explain why statins reduce cardiovascular events in both primary and secondary prevention independent of the magnitude of LDL lowering. PCSK9 inhibitors prevent degradation of LDL receptors, further enhancing LDL clearance. Ezetimibe blocks Niemann-Pick C1-like 1 (NPC1L1), reducing intestinal cholesterol absorption. Understanding these mechanisms is critical for appropriate lipid-lowering therapy selection.

Antiplatelet agents prevent arterial thrombosis in acute coronary syndromes and ischemic stroke. Aspirin irreversibly acetylates cyclooxygenase (COX), preventing thromboxane A2 synthesis, which is essential for platelet aggregation. P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) block the ADP receptor on platelets, preventing activation and aggregation. Anticoagulants prevent venous thrombosis and stroke in atrial fibrillation by interfering with the coagulation cascade. Warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, X), while unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) enhance antithrombin III activity against factors Xa and IIa. Direct oral anticoagulants (DOACs) target specific factors (Xa or IIa), providing predictable anticoagulation without monitoring. Understanding thrombotic mechanisms and drug pharmacokinetics is essential for preventing bleeding complications and drug interactions.

Cardiovascular disease and the conditions requiring pharmacological intervention arise from multiple etiologic pathways and risk factors:

Essential hypertension (90-95% of cases) results from multifactorial pathophysiology including excessive sympathetic nervous system activity, RAAS activation, endothelial dysfunction with impaired nitric oxide production, sodium sensitivity, and vascular smooth muscle dysfunction. Genetic predisposition (heritability ~30-50%) and environmental factors (high sodium intake, obesity, alcohol excess, sedentary lifestyle) contribute. Secondary hypertension (5-10% of cases) has identifiable causes: renal artery stenosis (atherosclerotic or fibromuscular dysplasia), primary aldosteronism (autonomous aldosterone secretion), pheochromocytoma (catecholamine excess), Cushing's syndrome, hyperthyroidism, sleep apnea, chronic kidney disease, and medication-induced (NSAIDs, oral contraceptives, sympathomimetics, anesthetic agents). Understanding whether hypertension is primary or secondary determines whether antihypertensive drugs alone suffice or whether specific treatment of the underlying cause is necessary.

CAD arises from atherosclerotic plaque formation in epicardial coronary arteries, with progression driven by endothelial dysfunction, lipid deposition (particularly oxidized LDL), inflammatory infiltration, smooth muscle proliferation, and fibrosis. Traditional risk factors include hyperlipidemia (elevated LDL, reduced HDL), diabetes mellitus (hyperglycemia promotes oxidative stress and inflammation), smoking (oxidative stress, platelet dysfunction, endothelial injury), hypertension (shear stress, vascular remodeling), obesity, sedentary lifestyle, and male sex or postmenopausal female status. Nontraditional risk factors include inflammatory markers (C-reactive protein), lipoprotein(a), homocysteine, and psychosocial stress. Plaque rupture with superimposed thrombosis (platelet aggregation, coagulation cascade activation) precipitates acute coronary syndromes (unstable angina, NSTEMI, STEMI). Long-standing ischemia without infarction leads to myocardial remodeling with fibrosis and chamber dilation. Cardiovascular drugs target multiple pathways in atherosclerosis: statins and PCSK9 inhibitors reduce LDL, antiplatelets prevent thrombosis, beta-blockers reduce oxygen demand, nitrates improve coronary perfusion, and ACE inhibitors/ARBs prevent remodeling.

Systolic heart failure (reduced ejection fraction, HFrEF) most commonly results from myocardial infarction with scar formation, chronic hypertension causing left ventricular hypertrophy and eventual decompensation, dilated cardiomyopathy (genetic, viral, inflammatory, alcohol-related, peripartum, or drug-induced such as from chemotherapy agents), and arrhythmias (chronic atrial fibrillation with rapid ventricular rate causing tachycardia-induced cardiomyopathy). Once ventricular function declines, neurohormonal activation (sympathetic nervous system, RAAS, natriuretic peptides) ensues as initial compensation but becomes maladaptive, driving further dysfunction and mortality. Diastolic heart failure (heart failure with preserved ejection fraction, HFpEF) results from impaired ventricular relaxation and compliance due to hypertension, diabetes, obesity, hypertrophic cardiomyopathy, restrictive cardiomyopathy, and constrictive pericarditis. ACE inhibitors, ARBs, beta-blockers, aldosterone antagonists, and SGLT2 inhibitors are cornerstone therapies because they counteract neurohormonal activation and prevent progressive remodeling. Diuretics manage congestion, inotropes (dobutamine, milrinone, low-dose dopamine) provide acute hemodynamic support in decompensation, and vasodilators (nitroprusside, nicardipine) reduce afterload in acute decompensated heart failure.

Supraventricular arrhythmias (atrial fibrillation, atrial flutter, supraventricular tachycardia) arise from enhanced automaticity (abnormal phase 4 depolarization in ectopic foci), triggered activity (early or delayed afterdepolarizations), or reentry (unidirectional conduction block with circulating activation). Atrial fibrillation is the most common sustained arrhythmia and results from atrial ectopic foci firing rapidly, often triggered by pulmonary vein activity in patients with structural heart disease (hypertension, CAD, valvular disease) or primary atrial disease. Rate control with beta-blockers, non-dihydropyridine CCBs, or digoxin and anticoagulation to prevent stroke are standard therapies. Ventricular arrhythmias (premature ventricular contractions, ventricular tachycardia, ventricular fibrillation) are life-threatening and typically occur in the setting of myocardial scarring (post-MI), cardiomyopathy, or ion channel abnormalities. Long QT syndrome (congenital or drug-acquired) predisposes to Torsades de Pointes, a polymorphic ventricular tachycardia. Brugada syndrome, Catecholaminergic polymorphic ventricular tachycardia (CPVT), and Short QT syndrome are other genetic channelopathies causing sudden cardiac death. Class III antiarrhythmics (amiodarone, sotalol, dofetilide) are used for severe ventricular arrhythmias, while implantable cardioverter-de

Statins: myalgia, myositis, and rare rhabdomyolysis (risk rises with CYP3A4 inhibitors and fibrates, especially gemfibrozil) plus asymptomatic transaminase elevation. Check CK only in symptomatic patients.

Diuretics: loop agents cause hypokalemia, hypomagnesemia, hyperuricemia, metabolic alkalosis, and ototoxicity; thiazides add hyponatremia, hypercalcemia, hyperglycemia; MRAs cause hyperkalemia and (spironolactone) gynecomastia.

Rate-slowing agents: beta blockers cause bradycardia, bronchospasm, and masking of hypoglycemia — overdose is reversed with glucagon. Non-dihydropyridine CCBs cause constipation, heart block, and negative inotropy; overdose is treated with IV calcium and high-dose insulin–euglycemia therapy. Dihydropyridines cause reflex tachycardia and dose-dependent ankle edema.

Reversal agents: vitamin K plus 4-factor PCC for warfarin, protamine for heparin, idarucizumab for dabigatran, andexanet alfa for factor Xa inhibitors. Nitroprusside can cause cyanide toxicity (hydroxocobalamin/sodium thiosulfate).